Abstract:We used miR‐146a−/− (KO) mice, a MF‐like model lacking driver mutations, to investigate whether pharmacological inhibition of JAK/STAT and/or NF‐κB pathways may reverse the myelofibrotic phenotype of these mice. Specifically, we tested the JAK1/2 inhibitor, ruxolitinib; the NF‐κB inhibitor via IKKα/β, BMS‐345541; both inhibitors in combination; or a dual inhibitor of both pathways (JAK2/IRAK1), pacritinib. Although all treatments decreased spleen size and partially recovered its architecture, only NF‐κB inhibition, either using BMS‐345541 (alone or in combination) or pacritinib, resulted in a reduction of extramedullary hematopoiesis, bone marrow (BM) fibrosis and osteosclerosis, along with an attenuation of the exacerbated inflammatory state (via IL‐1β and TNFα). However, whereas dual inhibitor improved anemia and reversed thrombocytopenia, the combined therapy worsened anemia by inducing BM hypoplasia. Additionally, combined treatment reduced both COL1A1 and IL‐6 production in an in vitro model mimicking JAK2‐driven fibrosis. In summary, NF‐κB inhibition reduces, in vitro and in vivo, disease burden, and BM fibrosis, which could provide benefits in myelofibrosis patients Emerging evidence shows the crucial role of inflammation (particularly NF‐κB pathway) in the development and progression of myelofibrosis (MF), becoming a promising therapeutic target. Furthermore, tailoring treatment with currently available JAK inhibitors (such as ruxolitinib or fedratinib) does not modify the natural history of the disease and has important limitations, including cytopenias. Since recent studies have highlighted the role of miR‐146a, a negative regulator of the NF‐κB pathway, in the pathogenesis of MF; here we used miR‐146a−/− (KO) mice, a MF‐like model lacking driver mutations, to investigate whether pharmacological inhibition of JAK/STAT and/or NF‐κB pathways may reverse the myelofibrotic phenotype of these mice. Specifically, we tested the JAK1/2 inhibitor, ruxolitinib; the NF‐κB inhibitor via IKKα/β, BMS‐345541; both inhibitors in combination; or a dual inhibitor of both pathways (JAK2/IRAK1), pacritinib. Although all treatments decreased spleen size and partially recovered its architecture, only NF‐κB inhibition, either using BMS‐345541 (alone or in combination) or pacritinib, resulted in a reduction of extramedullary hematopoiesis, bone marrow (BM) fibrosis and osteosclerosis, along with an attenuation of the exacerbated inflammatory state (via IL‐1β and TNFα). However, although dual inhibitor improved anemia and reversed thrombocytopenia, the combined therapy worsened anemia by inducing BM hypoplasia. Both therapeutic options reduced NF‐κB and JAK/STAT signaling in a context of JAK2V617F‐driven clonal hematopoiesis. Additionally, combined treatment reduced both COL1A1 and IL‐6 production in an in vitro model mimicking JAK2‐driven fibrosis. In conclusion, NF‐κB inhibition reduces, in vitro and in vivo, disease burden and BM fibrosis, which could provide benefits in myelofibrosis patients.

Perspective: Speculative role of Tmp21 mediated protein secretory pathway during endoplasmic reticulum (ER) stress induced chronic inflammation

NF-kappa B As a Central Mediator in the Induction of TGF-beta in Monocytes from Patients with Idiopathic Myelofibrosis: an Inflammatory Response Beyond the Realm of Homeostasis.

Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology

Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis

Abstract 7469: Inflammation plays an important role in the progression of chronic myeloid leukemia

Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression

A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis

Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology

Logical modelling of myelofibrotic microenvironment predicts dysregulated progenitor stem cell crosstalk

Inhibition of RhoA-mediated secretory autophagy in megakaryocytes mitigates myelofibrosis in mice

Critical role for the TGF-β1/mTORC1 signalling axis in defining the transcriptional identity of CTHRC1+ pathologic fibroblasts

Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis

Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis

EDA fibronectin–TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis

Recent advances in understanding myelofibrosis and essential thrombocythemia

miR‐146a−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype

Abstract P15: Aberrant Non-canonical NF-κB Signalling Reprograms the Epigenome Landscape to Drive Oncogenic Transcriptomes in Multiple Myeloma

Broad next generation integrated sequencing of myelofibrosis identifies disease-specific and age-related genomic alterations

The role of corticosteroids in the current treatment paradigm for myelofibrosis

PDIA2 Bridges Endoplasmic Reticulum Stress and Metabolic Reprogramming During Malignant Transformation of Chronic Colitis

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms